EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Focus on PD-1/PD-L1-Targeting Antibodies in Colorectal Cancer: Are There Options Beyond Dostarlimab, Nivolumab, and Pembrolizumab? A Comprehensive Review

Mateusz Kciuk iD, Katarzyna Wanke iD, Weronika Kruczkowska iD, Beata Marciniak iD, Renata Kontek iD

Molecules · 21.06.2025 · 30 (13) · 2686

DOI: 10.3390/molecules30132686 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 21.06.2025. Verfasst von Mateusz Kciuk und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biotechnology and Genetics, Faculty of Biology and Environmental Protection, University of Lodz, Banacha Street 12/16, 90-237…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, B7-H1 Antigen, Programmed Cell Death 1 Receptor, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 163 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The PD-1/PD-L1 pathway has emerged as a critical target in colorectal cancer (CRC) immunotherapy, with pembrolizumab, nivolumab, and dostarlimab demonstrating significant clinical efficacy, particularly in microsatellite instability-high (MSI-H) and mismatch repair-deficient (dMMR) tumors. However, a growing number of additional PD-1/PD-L1 inhibitors, including AMP-224, atezolizumab, avelumab, camrelizumab, durvalumab, envafolimab, sintilimab, spartalizumab, tislelizumab, and toripalimab, are currently under investigation, offering new possibilities for the expansion of treatment options. This review evaluates the therapeutic potential of these emerging agents, assessing their clinical development, mechanisms of action, and potential advantages over established therapies. Additionally, it explores key challenges such as primary and acquired resistance, limited efficacy in microsatellite-stable (MSS) CRC, and the complexities of combination strategies aimed at enhancing immunotherapeutic responses. By addressing these obstacles and highlighting prospects, this review provides insights into the evolving landscape of PD-1/PD-L1-targeted therapies in CRC and their potential to improve patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsB7-H1 AntigenProgrammed Cell Death 1 ReceptorImmune Checkpoint InhibitorsAntibodies, MonoclonalAntineoplastic Agents, ImmunologicalHumansAntibodies, Monoclonal, HumanizedNivolumabImmunotherapyMicrosatellite Instability

Stichwörter der Autor:innen

antibodiescolorectal cancerimmunotherapyprogrammed cell death

Substanzen

B7-H1 AntigenProgrammed Cell Death 1 ReceptorAntibodies, Monoclonal, HumanizedpembrolizumabNivolumabImmune Checkpoint InhibitorsAntibodies, MonoclonalCD274 protein, humandostarlimabPDCD1 protein, human

Autor:innen und Institutionen

  • Department of Molecular Biotechnology and Genetics, Faculty of Biology and Environmental Protection, University of Lodz, Banacha Street 12/16, 90-237 Lodz, Poland.
  • Department of Functional Genomics, Medical University of Lodz, 90-752 Lodz, Poland.

ORCID-Profile: Mateusz Kciuk, Katarzyna Wanke, Weronika Kruczkowska, Beata Marciniak, Renata Kontek

Zitieren

APA

Kciuk, M., Wanke, K., Kruczkowska, W., Marciniak, B., & Kontek, R. (2025). Focus on PD-1/PD-L1-Targeting Antibodies in Colorectal Cancer: Are There Options Beyond Dostarlimab, Nivolumab, and Pembrolizumab? A Comprehensive Review. Molecules, 30(13), 2686. https://doi.org/10.3390/molecules30132686

Vancouver

Kciuk M, Wanke K, Kruczkowska W, Marciniak B, Kontek R. Focus on PD-1/PD-L1-Targeting Antibodies in Colorectal Cancer: Are There Options Beyond Dostarlimab, Nivolumab, and Pembrolizumab? A Comprehensive Review. Molecules. 2025;30(13):2686. doi:10.3390/molecules30132686

BibTeX
@article{Kciuk2025,
  author = {Kciuk, Mateusz and Wanke, Katarzyna and Kruczkowska, Weronika and Marciniak, Beata and Kontek, Renata},
  title = {Focus on PD-1/PD-L1-Targeting Antibodies in Colorectal Cancer: Are There Options Beyond Dostarlimab, Nivolumab, and Pembrolizumab? A Comprehensive Review},
  journal = {Molecules},
  year = {2025},
  volume = {30},
  number = {13},
  pages = {2686},
  doi = {10.3390/molecules30132686}
}
Kostenlos starten →